^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    NXP900

    i
    Other names: NXP900, eCF506, NXP-900, NXP 900
    Company:
    Nuvectis Pharma
    Drug class:
    Src kinase inhibitor, YES1 inhibitor
    Related drugs:
    7ms
    Proteome-based molecular subtyping and therapeutic target prediction in gastric cancer. (PubMed, Mol Oncol)
    Application of kinase activity prediction algorithms and interrogation of gene dependency and drug sensitivity databases predicted that the mechanistic target of rapamycin kinase (mTOR) and dual specificity mitogen-activated protein kinase kinase 2 (MAP2K2) represented potential therapeutic targets for the EMT and metabolism subtypes, respectively, and this was confirmed using selective inhibitors. Overall, our study provides novel, in-depth insights into GC proteomics, kinomics, and molecular taxonomy and reveals potential therapeutic targets that could provide the basis for precision treatments.
    Journal
    |
    mTOR (Mechanistic target of rapamycin kinase) • MAP2K2 (Mitogen-activated protein kinase kinase 2)
    |
    sirolimus • NXP900
    1year
    A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers (clinicaltrials.gov)
    P1, N=40, Recruiting, Nuvectis Pharma, Inc. | Not yet recruiting --> Recruiting | Initiation date: Jun 2023 --> Oct 2023
    Enrollment open • Trial initiation date • Metastases
    |
    NXP900
    1year
    NXP900, a novel YES1/SRC kinase inhibitor demonstrates inhibition of YAP1 nuclear localization and potent single agent anti-tumor activity in esophageal squamous cancer models. (AACR-NCI-EORTC 2023)
    No abstract available
    Preclinical
    |
    YAP1 (Yes associated protein 1)
    |
    NXP900
    over1year
    A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers (clinicaltrials.gov)
    P1, N=40, Not yet recruiting, Nuvectis Pharma, Inc.
    New P1 trial • Metastases
    |
    NXP900